nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma
|
Moreno, Lucas |
|
|
136 |
C |
p. 52-68 |
artikel |
2 |
Anticancer drugs and COVID-19 antiviral treatments in patients with cancer: What can we safely use?
|
Gougis, Paul |
|
|
136 |
C |
p. 1-3 |
artikel |
3 |
Are immune checkpoint inhibitors a valid option for papillary renal cell carcinoma? A multicentre retrospective study
|
de Vries-Brilland, Manon |
|
|
136 |
C |
p. 76-83 |
artikel |
4 |
BRCA1 and BRCA2 pathogenic variant carriers and endometrial cancer risk: A cohort study
|
Kitson, Sarah J. |
|
|
136 |
C |
p. 169-175 |
artikel |
5 |
Corrigendum to ‘Dynamic risk assessment based on positron emission tomography scanning in diffuse large B-cell lymphoma: Post-hoc analysis from the PETAL trial’ [Eur J Canc 124 (January 2020) 25–36]
|
Schmitz, Christine |
|
|
136 |
C |
p. 207-208 |
artikel |
6 |
Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine?
|
Houot, Roch |
|
|
136 |
C |
p. 4-6 |
artikel |
7 |
COVID-19, palliative care and public health
|
Rodin, Gary |
|
|
136 |
C |
p. 95-98 |
artikel |
8 |
Critical reappraisal of phase III trials with immune checkpoint inhibitors in non-proportional hazards settings
|
Castañon, Eduardo |
|
|
136 |
C |
p. 159-168 |
artikel |
9 |
Defining the true impact of coronavirus disease 2019 in the at-risk population of patients with cancer
|
Angelis, Vasileios |
|
|
136 |
C |
p. 99-106 |
artikel |
10 |
Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trial
|
Conte, Benedetta |
|
|
136 |
C |
p. 43-51 |
artikel |
11 |
Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIRGEMAX)
|
Rinaldi, Yves |
|
|
136 |
C |
p. 25-34 |
artikel |
12 |
Genetic variants in TKT and DERA in the nicotinamide adenine dinucleotide phosphate pathway predict melanoma survival
|
Gu, Ning |
|
|
136 |
C |
p. 84-94 |
artikel |
13 |
High-dose chemotherapy in a patient with coronavirus disease (COVID-19)
|
De Giorgi, Ugo |
|
|
136 |
C |
p. 130-131 |
artikel |
14 |
Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer
|
van der Doelen, Maarten J. |
|
|
136 |
C |
p. 16-24 |
artikel |
15 |
Impact of the coronavirus disease 2019 pandemic on cancer treatment: the patients’ perspective
|
de Joode, K. |
|
|
136 |
C |
p. 132-139 |
artikel |
16 |
Innovative countermeasures can maintain cancer care continuity during the coronavirus disease-2019 pandemic in Korea
|
Lee, Soohyeon |
|
|
136 |
C |
p. 69-75 |
artikel |
17 |
Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I–III patients treated with standard therapy
|
Dieci, Maria Vittoria |
|
|
136 |
C |
p. 7-15 |
artikel |
18 |
Making sense of cross-trial comparisons for the frontline treatment of advanced-stage Hodgkin lymphoma
|
Lad, Deepesh P. |
|
|
136 |
C |
p. 113-115 |
artikel |
19 |
Paediatric Strategy Forum for medicinal product development for acute myeloid leukaemia in children and adolescents
|
Pearson, Andrew D.J. |
|
|
136 |
C |
p. 116-129 |
artikel |
20 |
Patients with sarcomatoid renal cell carcinoma – re-defining the first-line of treatment: A meta-analysis of randomised clinical trials with immune checkpoint inhibitors
|
Iacovelli, Roberto |
|
|
136 |
C |
p. 195-203 |
artikel |
21 |
Ponatinib in childhood Philadelphia chromosome–positive leukaemias: an international registry of childhood chronic myeloid leukaemia study
|
Millot, Frédéric |
|
|
136 |
C |
p. 107-112 |
artikel |
22 |
PROFAST: A randomised trial implementing enhanced recovery after surgery for highcomplexity advanced ovarian cancer surgery
|
Sánchez-Iglesias, José Luis |
|
|
136 |
C |
p. 149-158 |
artikel |
23 |
Prognostic nomogram in patients with metastatic adenoid cystic carcinoma of the salivary glands
|
Cavalieri, Stefano |
|
|
136 |
C |
p. 35-42 |
artikel |
24 |
Progression-free survival is a suboptimal predictor for overall survival among metastatic solid tumour clinical trials
|
Pasalic, Dario |
|
|
136 |
C |
p. 176-185 |
artikel |
25 |
RE: Fulvestrant falsely elevates oestradiol levels in immunoassays in postmenopausal women with breast cancer
|
Howell, Sacha J. |
|
|
136 |
C |
p. 204-205 |
artikel |
26 |
Relapsing intracranial germ cell tumours warrant retreatment
|
Callec, Laetitia |
|
|
136 |
C |
p. 186-194 |
artikel |
27 |
Response to letter commenting on: Fulvestrant falsely elevates oestradiol levels in immunoassays in postmenopausal women with breast cancer
|
Samuel, Evangeline |
|
|
136 |
C |
p. 206 |
artikel |
28 |
Therapeutic drug monitoring of imatinib in patients with gastrointestinal stromal tumours – Results from daily clinical practice
|
IJzerman, Nikki S. |
|
|
136 |
C |
p. 140-148 |
artikel |